CLAIMS

1. An immunogenic composition comprising a fusion polypeptide comprising all three of v1, v2 and v3 meningococcal fHbp, in combination with (i) a NHBA polypeptide (ii) a NadA polypeptide and (iii) meningococcal outer membrane vesicles prepared from strain NZ98/254, wherein the fHbp fusion polypeptide has an amino acid sequence of formula NH_2—A-[-X-L]$_3$-B—COOH, wherein each X is a different variant fHbp sequence, L is an optional linker amino acid sequence, A is an optional N terminal amino acid sequence, and B is an optional C terminal amino acid sequence, and wherein the variant fHbp sequences are in the order v2-v3-v1 from N- to C-terminus, and wherein the v2 fHbp sequence comprises the sequence of SEQ ID NO. 8, but is modified to introduce at residues S32 and L123 the stabilising mutations S32V and L123R, and wherein the v3 fHbp sequence comprises the sequence of SEQ ID NO. 9 but is modified to introduce at residues S32 and L126 the stabilising mutations S32V and L126R.

2. The composition of claim 1, wherein:

   - the fusion polypeptide includes at least one epitope from each of SEQ ID NOs: 7, 8, and 9 and, after administration to a mouse, can elicit antibodies which can recognise all three of (a) a polypeptide consisting of SEQ ID NO: 4 (b) a polypeptide consisting of SEQ ID NO: 5 (c) a polypeptide consisting of SEQ ID NO: 6;

   - the NHBA polypeptide can elicit antibodies which, after administration to a mouse, can bind to a polypeptide consisting of amino acid sequence SEQ ID NO: 13;

   and/or

   - the NadA polypeptide can elicit antibodies which, after administration to a mouse, can bind to a polypeptide consisting of amino acid sequence SEQ ID NO: 18.

3. The composition of claim 1 or 2, wherein the fusion polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 36, 37, and 38.

4. The composition of any one of claims 1-3, wherein: (a) the fHbp fusion polypeptide has amino acid sequence SEQ ID NO: 36, or SEQ ID NO: 38; (b) the NHBA polypeptide comprises amino acid sequence SEQ ID NO: 12; and (c) the NadA polypeptide has amino acid sequence SEQ ID NO: 19.

5. The composition of any one of claims 1-4, wherein fHbp, NHBA and NadA polypeptides are present at a concentration between 50-150µg/ml.

6. The composition of any one of claims 1-5, further comprising an aluminium hydroxide adjuvant.

7. The immunogenic composition of any one of claims 1-6, which is for protecting a mammal against a meningococcal infection.
8. The immunogenic composition according to claim 7 wherein said mammal is a human.